digiM

💊 📰 🔬 Big news from digiM! The FDA has purchased a subscription to the I2S cloud platform for image analytics and data management. Joshua Lomeo, digiM's Application Science Director, spoke on the license agreement: "Use of AI and cloud-based technologies comes with great responsibility in maintaining data integrity and security, and we feel privileged that the FDA has entrusted us with this. I2S is built from the ground up with the best principles in data accessibility and tracking in mind, including audit capabilities for FDA 21 CFR Part 11 Compliance. We are honored to support their work reviewing life-changing therapeutics." More info below! #drugdevelopment #drugspharmaceuticals #ai #imageprocessing #regulatory #fda #imageanalysis

Excited to talk about digiM and CMAC integrated service offering at CMAC open days! Thanks Daniel Treffer for capturing the moment!

We are thrilled to attend Open Days this week! Itay Speicher will be on site in Glasgow to share our latest solutions and an exciting collaboration formed with CMAC. We hope to see you there!

Synthetize drug product microstructures toward optimal performance while minimizing risks through different clinical phases. It is powerful, it is real, and it is here. Join our webinar for technology and business discussions Thursday, March 20, 2025. https://lnkd.in/eYXJyjGN

Our next webinar is coming up soon! In this webinar, we will be joined by our collaborators from Merck and Genentech to discuss the applications of our patented AI-structural synthesis methodology. Using images of the drug product, the technique allows the synthesis of new formulations, with transformations to the particle size, loading, and even transformation of 2D images into 3D images. We hope you can join us! https://lnkd.in/eYXJyjGN

We're thrilled to be attending Pittcon Conference + Exposition next week! Join us to discover the latest on how advanced microscopy is transforming drug development.

💡 🔬 💊 Our new technology solution page for dissoLab is live! See more below on how the platform is transforming particle design and dissolution method development. https://lnkd.in/e8RQPzDZ

Thrilled to have our product specialist Phillip Yawman share his perspectives on the criticality of amorphous dispersion morphologies, with the lens of processing and dissolution impacts!

The duration of drug release for oral dosage forms can be modified with a variety of enabling technologies and ingredients. With the introduction of these technologies, and thus a complex release mechanism, advanced understanding is often needed to optimize formulation selection, whether its selecting grade, amount, or manufacturing technique. In the case example below, we take a closer look at the functionality of a swellable methacrylic acid copolymer. micro-CT analysis enables advanced quantitative evaluation on the polymer's functionality and ability to extend release to the ideal target duration. At digiM we support critical decisions on these kinds of enabling technologies. For more info, see below: https://lnkd.in/eMV9ns5c

We are thrilled to attend the upcoming CMAC Open Days in Glasgow! Please join us to discover the latest in transformative approaches to manfuacturing and formulation. We will share of our latest technologies and applications, including the dissoLab platform for predictive dissolution assesment of drug products. We look forward to meeting our CMAC partners and sharing more about our exciting collaboration and its research outcomes! Registration below: https://lnkd.in/e2Gp7Kgx